TC Biopharm (Holdings) Plc is a biotechnology firm focused on developing cell therapies for cancer treatment, particularly in the UK and Europe. The company is pioneering the use of allogeneic gamma delta T cell therapies, which are designed to enhance the immune response against tumors, setting it apart from traditional therapies.
TC Biopharm primarily generates revenue through the development and commercialization of its proprietary cell therapies, which are currently in clinical trials. The company has a unique competitive advantage in its focus on gamma delta T cells, which are less likely to cause graft-versus-host disease compared to conventional T cell therapies, potentially leading to better patient outcomes.
Clinical trial results for lead product candidates
Regulatory approvals from the FDA or EMA
Partnership announcements with larger pharmaceutical companies
Market adoption rates of cell therapies
Regulatory changes affecting drug approval processes
Technological disruption in cell therapy methods
Emergence of alternative cancer therapies
Increased competition from larger biotech firms
High cash burn rate impacting liquidity
Potential need for additional funding to support clinical trials
low - The demand for biopharmaceuticals is generally less sensitive to economic cycles, as healthcare spending tends to remain stable.
Interest rates affect TC Biopharm primarily through the cost of financing for R&D. Higher rates could increase borrowing costs, impacting cash flow and investment in clinical trials.
minimal - The company has a manageable debt-to-equity ratio of 0.67, indicating limited reliance on credit.
growth - Investors looking for high-risk, high-reward opportunities in innovative biotech.
high - The stock has shown extreme volatility, with a 1-year return of -99.8%.